## Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023.

4		
5		
6		
7		
8	Fergus	Hamilton <sup>1,2</sup> , Elizabeth Darley <sup>2</sup> , Alasdair MacGowan <sup>2</sup>
9		
10		
11	1.	MRC Integrative Epidemiology Unit, University of Bristol
12	2.	Infection Science, North Bristol NHS Trust

л

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

13	
14	Introduction
15	
16	Fluoroquinolones are important, widely used antibiotics but have associations with a significant
17	number of adverse outcomes. A recent (January 2024) decision by the UK drug regulator, the
18	Medicines and Health Regulatory Authority (MHRA), restricted systemic use of these antibiotics
19	to when only absolutely necessary with immediate effect. One stated reason for the ban was
20	the failure of previous guidance (2019, 2023), to impact prescribing, with the 2023 MHRA Drug
21	Safety Update stating there had been "no change in prescribing" of fluoroquinolones in relation
22	to guidance.
23	
24	Methods
25	
26	We evaluated the trend in prescribing of fluoroquinolones and comparator antibiotics using
27	national data for all primary care practices in England from 2019 to 2023. We calculated the
28	percent change in prescribing of fluoroquinolones using linear regression, comparing with other
29	antibacterials Analyses were then performed at the integrated care board (ICB) level. We also
30	performed a similar analysis on secondary care prescribing and included hospital inpatient stay
31	data.
32 33	Results
33 34	Results
35 35	In primary care, there was a clear negative trend in fluoroquinolone (particularly ciprofloxacin)
36	item dispensing, with a 4.2% reduction in items dispended per year, 95% confidence interval, CI
37	(-5.2%; -3.3%, $p = 6 \times 10^{-13}$ ). This occurred despite no change in overall antibacterial
38	prescription $(+2\% - 0.56\%)$ ; +4.6%, p = 0.12) and no decrease in comparator antibiotics. These
39	occurred across nearly all (97/101) ICBs. Secondary care data showed stable prescription of
40	fluoroquinolones, but other comparator antibiotics increased, leading to relatively fewer
41	prescriptions compared to other agents.
42	
43	Conclusions
44	
45	There was a marked reduction in fluoroquinolone prescribing in primary care in England in both
46	absolute terms and relative to other antibiotics between 2019 to 2023. Relative reductions have
47	occurred in secondary care.
48	
49	Funding
50	
51	Wellcome Trust (222894/Z/21/Z)

## 52 Introduction

53

54 Fluoroquinolones are a widely used class of antibiotics.<sup>1</sup> They are effective therapy for Gram-55 negative, Gram-positive, and (for some agents) anaerobic bacteria.<sup>1</sup> The most commonly used 56 agents are ciprofloxacin, levofloxacin, and moxifloxacin, although the first two are far more 57 common. Given their broad spectrum of in-vitro activity and generally favourable 58 pharmacokinetics, they are widely recommended across a broad range of infection indications, 59 particularly in patients with penicillin allergy. They were (until very recent MHRA 60 announcements<sup>2</sup>) the recommended option for severe community acquired pneumonia (CAP) 61 with a penicillin allergy in UK National Institute for Clinical Excellence (NICE) guidance<sup>3</sup>. They 62 are also recommended in the 2019 Infectious Diseases Society of America/American Thoracic 63 Society (IDSA/ATS) pneumonia guidance,<sup>4</sup> and as first line and/or recommended in penicillin 64 allergy or under other conditions in conditions as broad as prosthetic joint infection, legionella pneumonia<sup>4</sup>, sexually transmitted infections<sup>5</sup>, typhoid fever<sup>6</sup>, pyelonephritis<sup>7</sup>, tuberculosis<sup>8</sup> and 65 66 Gram-negative infections including bacteraemia<sup>9</sup>. For some deep tissue infections they may be 67 given for a course lasting several weeks or months, and are the preferred therapy. Given the 68 paucity of effective oral agents for Gram negative infection and high resistance rates to other 69 drugs, fluoroquinolones are highly valuable agents. For infections caused by some organisms 70 such as Pseudomonas aeruginosa, they are the only oral option. 71 72 Despite these benefits, fluoroquinolones are known to associate with a range of adverse 73 events.<sup>10</sup> Well established and proven causal associations include tendonitis and C. difficile 74 infection, but over the past 20 years, an increasing number of associations have been identified 75 including QTc prolongation, aortic dissection, aortic aneurysm and (sometimes severe) psychiatric associations.<sup>10</sup> Regulators have been aware of these risks for some time, with the 76 77 first FDA 'black box' warning in 2008 (related to tendonitis).<sup>11</sup> More recently the European 78 Medicines Agency (EMA) and MHRA have produced multiple updates with increasing concern. 79 The EMA produced guidance suggesting use should be limited to only severe infection in March 2019 (due to the risk of tendonitis and potentially aortic dissection).<sup>12</sup> The MHRA have also 80 produced a number of updates, starting in 2019<sup>13</sup>, repeated in 2023<sup>14</sup>, and most recently, in 81 2024<sup>2</sup>, a much tighter restriction of fluoroquinolone prescribing. This directs against any use of

- 82 systemic fluoroquinolone therapy except where absolutely necessary (e.g. no other drug can be 83
- 84 used). The extent of this ban resulted from an ongoing review of the evidence, increasing
- 85 patient reports via the national scheme (Yellow Card), and "no evidence of a change in
- 86 fluoroquinolone prescribing patterns" in relation to previous warnings<sup>14</sup>.
- 87


88 The reference for this "lack of change" in prescribing was a European pharmacovigilance study<sup>15</sup>, which included 15 million UK participants from 2016 to 2020 and was commissioned by 89 90 the EMA to assess the impact of the 2019 EMA guidance across numerous countries. It was not able to identify a reduction in fluoroquinolone usage directly in relation to the EMA guidance.<sup>15</sup> 91 However, this study did show that a) the UK had the lowest rates of fluoroquinolone prescribing 92 93 in all included countries, and b) the UK had around a 3% reduction per year in fluoroquinolone 94 prescriptions from 2016 to 2020 guidance.<sup>15</sup>

96	Given this study ended during 2020 (when impact of the COVID-19 strongly impacted
97	antimicrobial prescribing) and showed an apparent reduction in prescribing we performed a
98	study of UK fluoroquinolone prescribing in primary care using all of England primary care and
99	secondary care data. Our primary aim was to identify the recent trend in fluoroquinolone
100	prescribing.
101	
102	
103	Methods:
104	
105	To evaluate trends in prescribing of fluoroquinolones, we extracted data on England wide
106	prescribing in both primary and secondary care datasets.
107	
108	
109	Primary care dataset
110	
111	Primary care data was accessed via OpenPrescribing <sup>16</sup> , which extracts directly from NHS
112	primary care records for England. We extracted specific data on quinolones (as a class),
113	ciprofloxacin, and levofloxacin. Fluoroquinolones are the only regularly prescribed quinolones
114	in the U.K and so we use the terms interchangeably in this report. Ciprofloxacin accounted for
115	>95% of prescriptions, and no other quinolone agents were prescribed widely.
116	
117	For comparison, we also extracted data on two comparator agents with similar spectrums of
118 119	activity: co-amoxiclav and co-trimoxazole. We also extracted total antibiotic use for all penicillins, all antibacterials, and total medication use. Data was available from December
119	2018 until November 2023 (4 years 11 months), at a monthly level, and at Integrated Care Board
120	level. There are 101 Integrated Care Boards in ?England. Data is in the format of number of
121	prescriptions and quantity dispensed (as most prescriptions are for more than one dose). We
122	estimated defined daily doses (DDDs) using BNF dosing (i.e. as ciprofloxacin is dosed twice
124	daily), the quantity divided by two is the DDD.
125	
126	Secondary care dataset
127	
128	Secondary care data was accessed via ( <u>https://hospitalmedicines.genomium.org/</u> ) <sup>17</sup> which in
129	turn extracts data from the NHSBSA SCMD dataset for England. <sup>18</sup> We extracted data on
130	ciprofloxacin and levofloxacin, as well as comparator agents with similar spectrum of activity:
131	co-amoxiclav , piperacillin-tazobactam, co-trimoxazole, meropenem, clarithromycin,
132	amoxicillin, and ceftriaxone. As this dataset reports chemical products, we defined piperacillin-
133	tazobactam by tazobactam sodium, co-trimoxazole by sulfamethoxazole, and amoxicillin-
134	clavulanate by potassium clavulanate. None of these are widely used outside the antibiotic
135	combination. Data was available from April 2019 until November 2023, at a monthly level.
136	
137	We estimated the number of prescriptions by assuming a 5-day course length for all infections
138	and assuming BNF standard dosing regimens. This led to one prescription being 5g for
139	Ciprofloxacin, 5g for levofloxacin, 15g for Meropenem, 15g for Amoxicillin, 5g for clarithromycin,
140	5g for Ceftriaxone 8g for co-trimoxazole (assuming 800mg per dose of sulfamethoxazole), 3g for

co-amoxiclav (assuming 200mg per dose of clavulanate, and IV therapy), and 7.5g for 141 piperacillin-tazobactam (assuming 500mg per dose of tazobactam). We recognise these are 142 assumptions and are simply produced to aid comparison with primary care prescribing. 143 144 145 Hospital data 146 147 From December 2020 until December 2023, NHS England produced monthly hospital utilisation data. This is in the format of number of occupied bed days per month and forms part of the 148 149 Urgent and Emergency Care Situation Report.<sup>19</sup> 150 151 Analytic approach 152 As there have been numerous warnings from multiple drug regulators including the FDA, MHRA, 153 154 and EMA over this time, and as the interventions are likely not applied instantaneously, we took 155 the approach of visualising and quantifying change over time, rather than performing an 156 analysis at a specific time point. This approach has also been shown to be highly sensitive to statistical methods and/or time points chosen.<sup>20</sup> Our datasets largely overlap although the first 157 major MHRA warnings and restriction occurred in March 2019, prior to our secondary care 158 159 dataset. 160 For this reason, and because of the increased potential for potentially less appropriate 161 prescribing occurs in primary care (due to the reduced severity of illness and reduced burden of 162 bacterial infection, and less use of fluoroquinolones in guidelines), we focus most of our 163 164 analysis on the primary care data but include the secondary care data for completeness. 165 166 We performed linear regression for each drug/drug class with date as the exploratory variable, with the scale set to evaluate changes in prescriptions per year. Absolute prescription rates 167 168 were calculated with respect to the total English population in the given year. To aid visualisation, we scaled some analyses so prescriptions on the first study month were the 169 reference, and report figures as a percentage change. As regional data (from ICBs) was available 170 171 for primary care data, we also ran analyses at the ICB level. 172 173 To compare with other classes/antibiotics, we performed a Z-test for the beta and standard error of the linear regression for each class.<sup>21</sup> For aid of visualisation, we also performed linear 174 175 regression of ratios (e.g. the ratio of co-amoxiclav to ciprofloxacin over calendar time). 176 177 Finally, for the time where it was available, we analysed data adjusted for inpatient population. 178 That is, we divided the number of prescriptions by the number of inpatients for each month to generate prescriptions/month/patient. 179 180 181 182 183 Software and codes 184

- 185 We used R v 4.31 for analyses, and used the *tidyverse* package for data wrangling and plotting.<sup>22</sup>
- 186 All code is available at https://github.com/gushamilton/floroquinolone, and the analysis is
- 187 completely replicable by running the same code locally. Regression was performed using the
- 188 linear regression model in R, while some plots fitted splines via ggplot.
- 189
- 190 *Ethics*
- 191
- 192 All data used in this analysis is publicly available. No ethics approval was therefore required.
- 193
- 194 *Funding*
- 195
- 196 FH's time was funded by the Wellcome Trust.

197 198 **Results:** 199 200 Our primary analysis focussed on primary care prescribing, where the risk-benefit ratio of fluoroquinolone prescribing is most questioned. Across the study period (~5 years), 201 151,144,401 prescriptions for antibacterial agents were given across England, with an 202 estimated population of 59.6 million (2021 census data<sup>23</sup>). This equates to 549 prescriptions per 203 year/1000 people. Approximately one fifth of this was made up of amoxicillin (125 prescriptions 204 205 per year per 1000 population). Fluoroquinolone represented a small proportion of antibiotics 206 prescribed (9 per year per 1000 population). This is visualised in Figure 1A. 207 208 Over the study period, antibacterial prescription was static (Figure 1B, +2% change per year; 209 95% CI -0.56% ; 4.6%, p = 0.12). However, fluoroquinolone prescription decreased substantially over time (-4.2% 95% CI -5.2%; -3.3%,  $p = 6 \times 10^{-13}$ , Figure 1C). This was driven by ciprofloxacin 210 211 reduction, which was 20 times more common than levofloxacin prescription. Figure 1D shows these changes scaled so the first month was set to 1 for all products. This change in 212 213 fluoroquinolone prescribing was offset by a large increase in co-trimoxazole prescribing 214 (change per year +7.5% 95% CI (6.5%; 8.5%),  $p = 4.4 \times 10^{-22}$ ). No other tested antimicrobial 215 changed substantially. **Table 1** shows all estimates, with Z-tests comparing change in trends 216 versus all fluoroquinolones. This showed the trend in fluoroquinolone prescription was reduced compared to all other antimicrobials. 217 218



product — Antibacterials — Clarithromycin — Co-amoxiclav — Co-trimoxazole — Fluoroquinolones

Figure 1: Panel A shows the items dispensed per year per 1000 population for a variety of antimicrobials and antimicrobial classes over the whole study period. Panel B shows the change over time in prescription of various antimicrobials: clarithromycin, co-amoxiclav, cotrimoxazole, and fluoroquinolones. All antibacterial usage over this time is plotted. Panel C 

shows just fluoroquinolones to help visualise the change, while, panel D shows the same as 

Panel B but rescaled so each drug class starts at 1. Linear regression lines shown with 95% CI.

236	
237	
238	
239	
240	
241	Table 1: Estimates of the change in prescribing per year of each agent across the primary care
242	study period.
243	

P value for Z-test

Agent	% change per year (95% CI)	P value	against trend for all fluoroquinolones*
Ciprofloxacin	-5.1% (-6% ; - 4.2%)	4.0e-16	8.9e-02
Fluoroquinolones	-4.2% (-5.2% ; - 3.3%)	6.2e-13	NA
Co-amoxiclav	-0.84% (-2.1% ; 0.37%)	1.7e-01	3.8e-06
Clarithromycin	-0.61% (-3.9% ; 2.7%)	7.1e-01	1.8e-02
Overall	2% (1.2% ; 2.7%)	3.7e-06	2.0e-25
Antibacterials	2% (-0.56% ; 4.6%)	1.2e-01	2.2e-06
Amoxicillin	2.5% (-2.4% ; 7.4%)	3.1e-01	3.5e-03
Penicillins	2.8% (-0.72% ; 6.2%)	1.2e-01	4.9e-05
Levofloxacin	3.8% (1.7% ; 5.8%)	5.7e-04	7.3e-13
Co-trimoxazole	7.5% (6.5% ; 8.5%)	4.4e-22	9.1e-69

<sup>244</sup> \*Z-test relative to fluoroquinolone coefficient, calculated as per.<sup>21</sup> This compares whether there

is a difference between these two estimates (i.e. a difference in trend between the two agents).

- 246
- 247
- 248

There are 101 Integrated Care Boards (ICBs) in England. Over this period, only five care boards


reported an increase in fluoroquinolone usage, with only one (West Leicestershire, +3.1% 95%

CI, 1.5%; 4.7%, 2.8 x  $10^{-4}$  being measured with any statistical confidence (Figure 2,

252 **Supplementary Table 1**). In contrast, the majority of ICBs had large reductions in

fluoroquinolone usage, with 37% of ICBs reducing their prescription by 5% or more per year. The biggest reduction came from NHS Oldham ICB, with a reduction in fluoroquinolone usage by -12% per year 95% CI (-65% ; -47%, p = 1 x  $10^{-23}$ ). 





261 Figure 2: Panel A shows changes in prescribing of fluoroquinolones across ICBs. Multiple linear regression lines across all 101 ICBs are fitted. Each line represents an ICB, with the faded 262 dots representing prescribing at that given month. Panel B shows the change per year for each 263 ICB plotted as a histogram. The black line represents no change per year, while the dotted red 264 265 line represents the overall change per year in England.

266 267

268 We then analysed data in secondary care. This is slightly more challenging as the weight of each 269 product in grams is provided, and then this was converted (assumptions in Methods) to 270 estimate and compare with the primary care data. In Figure 3, we compared estimates for 271 multiple antimicrobial classes in primary and secondary care. Fluoroquinolone usage was 272 generally higher in secondary care (around 50% higher total prescriptions), in contrast to 273 amoxicillin and clarithromycin, which were much more common in primary care. Co-274 trimoxazole usage was much higher in secondary care. There was much more variability in 275 secondary care prescribing, particularly in early 2020, likely related to variability in hospital 276 occupancy rates the and cancellation of much elective surgery during the COVID-19 277 pandemic. Unlike in primary care, there were no clear trends identified for ciprofloxacin, 278 clarithromycin, or amoxicillin prescriptions over time in secondary care. However, there was 279 increasing usage of co-amoxiclay, co-trimoxazole, ceftriaxone, levofloxacin, and piperacillin-280 tazobactam, over this period (all p < 0.001, Table 2).

281

Performing a Z-test comparing the regression coefficients, we identified evidence that all these 282 agents had increased prescribing relative to ciprofloxacin prescribing (Z-score p values in Table 283

2). This data suggests that although ciprofloxacin usage has been stable in secondary care 284


285 (+0.11% 95% CI, -1.7%; 1.9%), the usage of comparable agents with similar spectra of activity

286 has increased relative to ciprofloxacin. Levofloxacin usage did increase over this time period

 $(+6.2\% 95\% \text{ CI}, 3\%; 9.3\%, \text{p} = 2 \times 10^{-4}$ , but again, relatively less co-trimoxazole and piperacillin-287

tazobactam (both p < 0.001), and with a similar increase to ceftriaxone. 288

289



## 291

292 Figure 3: Prescribing (items/month) of various antimicrobial agents in primary and secondary

293 care. Data taken from different sources and transformations applied, so interpret raw

- 294 comparisons with caution. Linear regression with 95% confidence intervals fitted.
- 295

Table 2: Relative rates of prescribing of various antimicrobial agents in secondary care. The
 second column provides the percentage change per year, while the last two columns compare
 whether the trend is different to the ciprofloxacin or levofloxacin trend.

- 299
- 300 301
- 302


Agent	% change per year, (95% CI)	p-value	p-value for Z-test against Ciprofloxacin	p-value for Z-test against Levofloxacin
Co- trimoxazole	11% (9.9%;13%)	4.3e-21	1.1e-22	1.4e-03
Tazobactam	6.7% (5% ; 8.4%)	1.3e-10	3.3e-08	3.9e-01
Levofloxacin	6.2% (3% ; 9.3%)	2.3e-04	3.6e-04	5.0e-01
Ceftriaxone	5.1% (2.9%;7.3%)	1.9e-05	1.8e-04	2.9e-01
Amoxicillin	3.7% (1.4%;6%)	2.5e-03	7.1e-03	1.0e-01
Co-amoxiclav	3.3% (1.4%; 5.2%)	8.1e-04	6.3e-03	5.7e-02
Ciprofloxacin	0.11% (-1.7%; 1.9%)	9.0e-01	5.0e-01	3.6e-04
Meropenem	-0.65% (-2%; 0.72%)	3.5e-01	2.5e-01	3.2e-05
Clarithromycin	-3.2% (-6.3%;- 0.11%)	4.3e-02	3.1e-02	9.8e-06

303

\*Z-test relative to ciprofloxacin coefficient, calculated as per.<sup>21</sup> This compares whether there is
 a difference between these two estimates (i.e. a difference in trend between the two agents).

306

To aid comparison, a final plot showing the ratio of prescribing relative to ciprofloxacin is shown in **Figure 4**. This shows that over the study period, the relative prescribing of ciprofloxacin has fallen. At the start of 2020, approximately 3 prescriptions containing amoxicillin were given for each ciprofloxacin prescription, by late 2023, this was nearly 4. This trend is shown for all tested agents except meropenem, clarithromycin, and levofloxacin, which has a relative increase compared to ciprofloxacin (although small on the absolute terms, of 0.36% per year).



316

Figure 4: The relative ratio of prescription of each of the above antibacterial agents in secondary
 care, as compared to ciprofloxacin, over time. Linear regression fitted with 95% confidence
 intervals.

320

321

Finally, from December 2020, we had access to monthly bed occupancy from NHS England and 322 323 used this to adjust and generate estimated prescriptions per admitted person per month. This 324 period starts >1 year after the MHRA and EMA warnings, and inspection of Figure 3 shows an 325 already steep drop in ciprofloxacin prescribing between 2020 and 2021 of around 15%, which would not be captured in this analysis. Between December 2020 and December 2023, there 326 327 was a large rise in occupied beds, from around 78,000 to 92,000 inpatients (~15% increase, 328 Supplementary Figure 1). When adjusting for hospital bed utilisation, we identified a reduction 329 in ciprofloxacin (but not levofloxacin usage), with -2% reduction in prescribing per year 95% CI (-3.9%; -0.15%, p = 0.04, Figure 5). Given the steep drop prior to this time period this analysis 330

- 331 shows that relative to hospital utilisation, reductions in secondary care prescribing are similar,
- although slight smaller, than in primary care for ciprofloxacin. In contrast, levofloxacin
- prescription did increase (+4.5% 95% CI +0.63% ; +8.3%), meaning overall fluoroquinolone
- 334 prescriptions were stable (-0.8%; 95% CI -2.5%; +0.8%).
- 335






Figure 5: Prescriptions of each agent, adjusted for hospital utilisation, so the Y-axis is on the
 scale of prescriptions per inpatient per month. Linear regression (blue line) fitted with 95% CI
 (grey area)

340

341

## 343 Discussion:

344

Our work uses both primary and secondary care data for the whole of England to explore
fluoroquinolone prescriptions over the last five years and assess the influence of EMA/MHRA
restrictions on prescribing. We identified clear reductions in primary care prescribing of
ciprofloxacin, which accounted for the vast majority of all primary care fluoroquinolone
prescriptions. This was in contrast to usage of comparator antibiotics that were largely static.
In secondary care, antimicrobial prescribing varied much more, likely due to the COVID-19

pandemic. Absolute ciprofloxacin prescribing was stable across the time period. However,
comparator antibiotic prescriptions increased, consistent with a relative reduction in
ciprofloxacin prescribing. For the time period from December 2020 onwards (by which time a
~15% reduction in ciprofloxacin prescribing had occurred), we had hospital utilisation data.
When adjusting for this, relative ciprofloxacin usage reduced by around 2% per year. This is
consistent with increased pressure and workload on the NHS in England, while maintaining

relatively infrequent use of fluoroquinolones compared to other agents ?. Levofloxacin
 prescription did, however, increase.

360

361 One major reason for the continued use of fluoroquinolones in secondary care is that there are remarkably few good oral options for the therapy of some infections. Potential agents often 362 require intravenous administration, and there is also pressure to reduce the use of certain other 363 agents (e.g. third generation cephalosporins, Beta-lactam-beta-lactamase inhibitors and 364 carbapenems). Resistance rates to co-trimoxazole and co-amoxiclav in Gram negatives are 365 ~30%, with ciprofloxacin at only 17% in the recent ESPAUR report.<sup>24</sup> Additionally, some 366 367 randomised trial data and meta-analyses, particularly in pneumonia, suggests that 368 fluoroquinolones are superior to other options in this condition, which is the main reason for antimicrobial prescribing in acute admissions.<sup>25</sup> Other indications for fluoroquinolones may be 369 relatively uncommon in terms of proportional numbers of patients affected, but by their nature 370 371 require prolonged courses for up to 3-6 months, for example prosthetic joint or vascular 372 implant infection.

373


374 As far as we are aware, the only other study examining post EMA/MHRA fluoroquinolone 375 prescribing trends is Ly et al, funded by the EMA and analysing UK data from 2016-2020<sup>15</sup>. This 376 study used a multisegmented regression approach to identify monthly percentage changes in 377 relation to specific communications from regulators. Although this study is reported in the 378 MHRA Drug Safety Update as showing 'no change' in prescribing, it does show a reduction in 379 fluoroquinolone prescribing, and is estimated by Ly et al to be "at best, a reduction in prescriptions of around 25%".<sup>15</sup> As such, our results are concordant and extend the study period 380 and show further reductions since then. The English Surveillance Programme for Antimicrobial 381 Utilisation and Resistance (ESPAUR) report for 2023 provides supportive data, with quinolone 382 prescription dropping from 0.565 in 2018 to 0.456 in 2022 (p = 0.04).<sup>24</sup> Interestingly, a study of all 383 384 antimicrobial prescribing over a longer period (2014-2024), identified a reduction in overall 385 antibiotic prescribing, whereas our data suggested largely static antimicrobial prescribing.<sup>26</sup> 386

387 Limitations of our study include its entirely ecological focus. We had no access to individual level data, and so we can only focus on trends without deeper insight. Interpretation of our 388 389 secondary care data was reliant on transformation of product weight into assumed product 390 courses, although these transformations would only change absolute differences between 391 comparator antibiotics, and not changes in trend. Our use of hospitalisation data as a proxy for hospital pressure is imperfect, and only reflects total inpatients (not, e.g. admissions). Given 392 393 fluoroquinolones are used in both acute admissions and inpatients, it would be challenging to 394 accurately model hospital pressure, and inpatient hospitalisation is a reasonable proxy. 395 396 397 In summary, national prescribing data for England shows an approximate 5% reduction per year 398 in ciprofloxacin prescribing in primary care, where there is the most concern about 399 'inappropriate' prescribing of this drug class. This is clearly a large, statistically precise, and 400 important reduction, which has continued over the 5-year period however the exact reasons for 401 this reduction cannot be determined from this data. 402 403 404

Funding			
FH's time was funded by the Wellcome Trust (222894/Z/21/Z)			
Competing interests:			
No a	No author declares any competing interests.		
Pofe	erences:		
nen			
1.	Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev [Internet] 1989;2(4):378–424. Available from: http://dx.doi.org/10.1128/CMR.2.4.378		
2.	Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate [Internet]. Gov.uk. 2024 [cited 2024 Feb 3];Available from: https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-		
	must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-		
	inappropriate		
3.	Overview   Pneumonia in adults: diagnosis and management   Guidance   NICE. [cited 2024 Feb 3];Available from: https://www.nice.org.uk/guidance/cg191		
4.	Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community- acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med [Internet] 2019;200(7):e45–67. Available from: http://dx.doi.org/10.1164/rccm.201908-1581ST		
5.	Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS [Internet] 2020;31(1):4–15. Available from: http://dx.doi.org/10.1177/0956462419886775		
6.	Nabarro LE, McCann N, Herdman MT, et al. British infection association guidelines for the		
	diagnosis and management of enteric fever in England. J Infect [Internet] 2022;84(4):469– 89. Available from: http://dx.doi.org/10.1016/j.jinf.2022.01.014		
7.	Overview   Pyelonephritis (acute): antimicrobial prescribing   Guidance   NICE. [cited 2024		
	Feb 3];Available from: https://www.nice.org.uk/guidance/ng111		
8.	WHO consolidated guidelines on tuberculosis [Internet]. World Health Organization; 2022 [cited 2024 Feb 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK588564/		
9.	Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram- Negative Infections. Clin Infect Dis [Internet] 2023;Available from: http://dx.doi.org/10.1093/cid/ciad428		
	Con No a Refe 1. 2. 3. 4. 5. 6. 7. 8.		

445 446 447	10.	Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr [Internet] 2021;44(5):161–4. Available from: http://dx.doi.org/10.18773/austprescr.2021.035
448 449 450 451 452	11.	Center for Drug Evaluation, Research. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes [Internet]. U.S. Food and Drug Administration. 2019 [cited 2024 Feb 3];Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces- safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side
453 454 455 456	12.	Quinolone- and fluoroquinolone-containing medicinal products - referral [Internet]. [cited 2024 Feb 2];Available from: https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-and- fluoroquinolone-containing-medicinal-products
457 458 459 460 461	13.	Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [Internet]. Gov.uk. 2019 [cited 2024 Feb 3];Available from: https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects
462 463 464 465	14.	Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects [Internet]. Gov.uk. 2023 [cited 2024 Feb 2];Available from: https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects
466 467 468 469	15.	Ly NF, Flach C, Lysen TS, et al. Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post- Referral Prescribing Trends. Drug Saf [Internet] 2023;46(4):405–16. Available from: http://dx.doi.org/10.1007/s40264-023-01286-4
470 471	16.	Bennett Institute for Applied Data Science, University of Oxford. OpenPrescribing [Internet]. , 2024 [cited 2024 Feb 2];Available from: https://openprescribing.net/
472 473 474	17.	Sanderson T. A web tool for the exploration of hospital prescription data in England [Internet]. medRxiv. 2023 [cited 2024 Feb 2];2023.12.14.23299817. Available from: https://www.medrxiv.org/content/10.1101/2023.12.14.23299817v1.abstract
475 476	18.	NHS Business Authority. NHS SCMD. Available from: https://opendata.nhsbsa.net/dataset/secondary-care-medicines-data-indicative-price
477 478 479	19.	Statistics. Critical Care and General Acute Beds (NHS England) [Internet]. [cited 2024 Feb 3];Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/hospital-activity/monthly-hospital-activity/mar-data/
480 481	20.	Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, McKenzie JE. Comparison of six statistical methods for interrupted time series studies: empirical evaluation of 190

482		published series. BMC Med Res Methodol [Internet] 2021;21(1):134. Available from:
483		http://dx.doi.org/10.1186/s12874-021-01306-w
484	21.	Clogg CC, Petkova E, Haritou A. Statistical Methods for Comparing Regression Coefficients
485		Between Models. Am J Sociol [Internet] 1995;100(5):1261–93. Available from:
486		https://doi.org/10.1086/230638
487	22.	Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw
488		[Internet] 2019;4(43):1686. Available from:
489		https://joss.theoj.org/papers/10.21105/joss.01686
490	23	Roskams M. Population and household estimates, England and Wales - Office for National
491	20.	Statistics [Internet]. 2022 [cited 2024 Feb 10];Available from:
492		https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/popula
493		tionestimates/bulletins/populationandhouseholdestimatesenglandandwales/census2021
494		unroundeddata
405	0.4	11/11/20 English surveillance are granned for antimizer historial utilization and resistance
495	24.	UKHSA. English surveillance programme for antimicrobial utilisation and resistance
496		(ESPAUR). 2023; Available from:
497 408		https://assets.publishing.service.gov.uk/media/6555026e544aea000dfb2e19/ESPAUR-
498		report-2022-to-2023.pdf
499	25.	Choi S-H, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Respiratory
500		fluoroquinolone monotherapy vs. $\beta$ -lactam plus macrolide combination therapy for
501		hospitalized adults with community-acquired pneumonia: A systematic review and meta-
502		analysis of randomized controlled trials. Int J Antimicrob Agents [Internet]
503		2023;62(3):106905. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2023.106905
504	26.	McCloskey AP, Malabar L, McCabe PG, Gitsham A, Jarman I. Antibiotic prescribing trends in
505		primary care 2014-2022. Res Social Adm Pharm [Internet] 2023;19(8):1193–201. Available
506		from: http://dx.doi.org/10.1016/j.sapharm.2023.05.001
507		
508		
509	Sur	plementary Figures:
510	Sup	





512 **Figure S1**: Bed utilisation in English NHS trusts from December 2020 until December 2023.

- 513 Data from NHS England.
- 514
- 515
- 516